Answers are grounded in this paper and cite their sources.
Cohort study reveals EGFR T790M as the primary resistance mechanism in EGFR-mutant lung cancers, highlighting diverse molecular pathways of acquired EGFR-TKI resistance.
This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy. We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histologic transformation occur less frequently. More comprehensive methods to characterize molecular alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: